Wealthcare Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Wealthcare Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9	Closed	-$1K	–	367
2021 Q1	$1K	Buy	+9	New	+$1.48K	﹤0.01%	683
2015 Q3	–	Sell	-25	Closed	–	–	322
2015 Q2	$0	Sell	25 -300	-92%	-$53.9K	﹤0.01%	640
2015 Q1	$56K	Buy	+325	New	+$55.8K	0.01%	228

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthcare Capital Management's JAZZ Position: Q2 2021 in Review

Wealthcare Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2021, closing a stake of 9 shares — an estimated $1K sold.

Wealthcare Capital Management first reported a position in JAZZ in Q1 2015 and held it in 3 quarters. The position peaked at $56K in Q1 2015. 505 funds tracked by Wall St. Rank hold JAZZ as of Q2 2021.

Wealthcare Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Capital Management sold 9 Jazz Pharmaceuticals shares in Q2 2021, an estimated $1K.
Wealthcare Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 3 quarters.
Wealthcare Capital Management's Jazz Pharmaceuticals position peaked at $56K in Q1 2015.
505 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2021.

Based on Wealthcare Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.